NICE National Institute for Health and Care Excellence

Resource impact summary report

Resource impact
Published: 24 June 2026

www.nice.org.uk

© NICE 2026. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).

Contents

© NICE 2026. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).

Resource impact summary report

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Population and treatments' and 'Unit costs' worksheets in the template to reflect local data and assumptions.

Guidance recommendations

See NICE's recommendations on daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable.

Financial and capacity resource impact

The company has a commercial arrangement (commercial access agreement). This makes daratumumab available to the NHS with a discount. The size of the discount is commercial in confidence.

Users can input the confidential price of daratumumab and amend other variables in the resource impact template.

The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.

Clinical trial evidence shows that daratumumab plus bortezomib, lenalidomide and dexamethasone increases how long people have before their condition gets worse and how long they live compared with bortezomib, lenalidomide and dexamethasone.

Table 1 shows the impact on capacity activity in each of the next 3 years.

Table 1 Capacity impact (activity) in England

Year	Number of administrations
Current practice	152,889

© NICE 2026. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).

Year	Number of administrations
Year 1	171,960
Year 2	183,782
Year 3	191,032

There will be a capacity increase due to an increase in administrations. The increase in administrations is due to the estimated increase in uptake for both daratumumab with bortezomib, lenalidomide and dexamethasone and isatuximab with bortezomib, lenalidomide, and dexamethasone.

For further analysis, or to calculate the financial and capacity impact from a commissioner and provider perspective, see the resource impact template.

Eligible population for daratumumab with bortezomib, lenalidomide and dexamethasone

For this evaluation, the company asked for daratumumab with bortezomib, lenalidomide and dexamethasone to be considered only for untreated multiple myeloma in adults when an autologous stem cell transplant (ASCT) is unsuitable. This does not include everyone that it is licensed for.

Table 2 shows the population who are eligible for daratumumab with bortezomib, lenalidomide and dexamethasone and the number of people who are expected to have the treatment, excluding forecast population growth.

Table 2 Population expected to be eligible for and have daratumumab with bortezomib, lenalidomide and dexamethasone in England

Eligible population and uptake	Number of people eligible	Uptake for (%)	Number of people starting treatment each year	Number of people continuing treatment from previous years	Number of people having treatment each year
Current practice	3,152	0	0	0	0
Year 1	3,152	20	630	0	630
Year 2	3,152	30	946	630	1,576
Year 3	3,152	40	1,261	1,576	2,837

© NICE 2026. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).

The following assumptions have been used to calculate the eligible population:

- The number of people who are diagnosed with multiple myeloma is around 5,900 each year in England (Cancer Registration Statistics, England 2023).
- The company submission in line with assumptions from TA1098 estimates 67% of people with multiple myeloma are ineligible for ASCT.
- Clinical expert opinion is that 80% of people with multiple myeloma who are ineligible for ASCT will have treatment.

The future uptake for daratumumab with bortezomib, lenalidomide and dexamethasone is based on clinical expert opinion.

Treatment options for the eligible population

Usual treatment for adults with untreated multiple myeloma when an ASCT is unsuitable includes:

- daratumumab plus lenalidomide and dexamethasone (TA917)
- isatuximab plus bortezomib, lenalidomide and dexamethasone (TA1098).

For more information about the treatments, such as dose and average treatment duration, see the resource impact template.

Key information

Table 3 Key information

Time from publication to routine commissioning funding	90 days
Programme budgeting category	02I cancer, Haematological
Commissioner	NHS England
Provider	NHS Hospital trusts
Pathway position	Untreated multiple myeloma when a stem cell transplant is unsuitable

© NICE 2026. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).

About this resource impact summary report

This resource impact summary report accompanies the NICE technology appraisal guidance on daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable and should be read with it.

ISBN: 978-1-4731-9575-2

© NICE 2026. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).